SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  15     ISSUE:  12  December   2017 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN

 MBBS, MBA

MD. SAIFUL ALAM

 MBBS, MPH

EDITORIAL

Dear Doctor,

Welcome to this edition of "e- SQUARE".

This time, we have focused on some interesting features like -
"
Opioid Addiction !", "HIV Resistance !", "Food Allergies !", "Alzheimer's !",  "Gene Therapy !", "New Caner Drug !".

In our regular feature, we have some products information of SQUARE Pharmaceuticals Ltd. as well.

Please send your feedback !  We always value your comments !

On behalf of the management of SQUARE, we wish you all a very happy, healthy and prosperous life.

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals Ltd.

 Opioid Addiction !  

                                        Once-Monthly Injection Approved for Opioid Addiction

Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration. Opioid abuse is diagnosed when a person's pattern of opioid use leads to significant impairment or distress and includes signs and symptoms that reflect compulsive, prolonged self-administration of opioid substances for no legitimate medical purpose, or opioids are taken in far higher-than-recommended doses, the agency said in a news release. The drug buprenorphine has been shown to reduce opioid withdrawal symptoms and the desire to use opioids, without causing the cycle of highs and lows associated with opioid misuse or abuse, the FDA said. Everyone who seeks treatment for opioid use disorder deserves the opportunity to be offered the treatment best suited to the needs of each individual patient, in combination with counseling and psychosocial support, as part of a comprehensive recovery plan. Sublocade was evaluated in clinical studies involving nearly 850 adults who were diagnosed with moderate-to-severe cases of the disorder. The most common side effects included constipation, nausea, vomiting, headache, drowsiness and injection-site pain. Sublocade's safety and effectiveness were not evaluated in people under age 17.

SOURCE: HealthDay News, December 2017

Return to top

 HIV Resistance !

                                    HIV Is Gaining Resistance to Lifesaving Drugs

A new study warns of a potential return to the bad old days when there were no effective drugs to fight HIV, the virus that causes AIDS. Timed for release on Dec. 1, World AIDS Day, the new study looked at data on more than 56,000 adults living with HIV in sub-Saharan Africa, Asia and Latin America. In total, patients in 63 low- and middle-income countries were screened, and all began or restarted treatment with antiretroviral drugs between 1996 and 2016. The study found that the virus is gaining resistance to the lifesaving medicines. Resistance to the drugs increased between 2001 and 2016 and is approaching and exceeding 10 percent of people tested. Drug resistance was increasing fastest in countries in Eastern and Southern Africa. If the trend continues, the researchers warned, even a resistance rate of 10 percent or more would mean 890,000 more deaths from AIDS in sub-Saharan Africa by 2030, along with 450,000 new infections. Patients with drug resistance were more likely to have previously taken antiretroviral drugs, often during pregnancy, said by lead researcher. Treatments for HIV have improved immensely in recent years, and close to 21 million people worldwide are now being treated with antiretroviral therapy. Yet to end the AIDS epidemic as a public health threat, minimizing drug resistance will be one part of the response. Many people develop drug resistance after being treated by antiretroviral drugs if they stop taking their medication often due to personal reasons, difficulty accessing treatment providers, or drug supply issues that are common in low-income regions. When these individuals restart treatment at a later date, they are less likely to respond to therapy and may pass on the drug-resistant strains to other people.

SOURCE: HealthDay News, December 2017

Return to top

 
 
 Food Allergies !

                                                 New Hope for Kids with Multiple Food Allergies

A treatment for kids with more than one dangerous food allergy shows promise in early trials, the lead researcher said. Almost one-third of people with a food allergy have reactions to more than one type of food. This can increase the risk of accidental exposure and life-threatening anaphylaxis, according to top researcher.No treatment exists for multiple food allergies. Usually, patients are told to avoid the food triggers, but this requires constant attention to their diet. Patients find it very hard to live with multiple food allergies. It puts a huge social and economic burden on families. In this new study, scientists combined the asthma drug omalizumab with immunotherapy for 48 children with more than one food allergy. Immunotherapy exposes patients to tiny amounts of the foods that cause their allergic reactions. Gradually, the allergen dose is increased until the patient can tolerate normal amounts of the food. Taking omalizumab appeared to speed up the desensitization process without sacrificing safety, the lead researcher said. This could be a very promising way to decrease the burden of living with food allergies," said by lead researcher. Although the results are preliminary, they suggest that kids with multiple food allergies might one day be safely desensitized to their trigger foods using this treatment combination, and still further research is needed to confirm the findings before the treatment becomes available. The study participants were randomly assigned to receive the combined allergy treatment or a placebo. They were 4 to 15 years old and were allergic to a variety of foods, including almonds, cashews, eggs, hazelnuts, milk, peanuts, sesame, soy, walnuts and wheat. The children received omalizumab or a placebo for eight weeks before starting immunotherapy and for eight weeks during combination treatment with immunotherapy for two to five trigger foods. The participants then continued immunotherapy without the drug for an additional 20 weeks. The lead researcher found that 83 percent of the treatment group could tolerate a small dose of two food allergens versus 33 percent who took the placebo. The study showed significant improvements in safety and effectiveness in multi-allergic patients treated with omalizumab and food immunotherapy.

SOURCE: HealthDay News, December 2017

Return to top

 
 
 Alzheimer's !

                                                                    There's Still No Proven Way to Prevent Alzheimer's

Medical science has failed to prove that any treatment, therapy or brain exercise can help prevent dementias such as Alzheimer's disease, an extensive new review has concluded. No medications, over-the-counter remedies or brain training programs have been proven in solid clinical trials to ward off dementia, researchers with the Minnesota Evidence-Based Practice Center in Minneapolis stated after reviewing dozens of previously published studies. The upshot is there isn't a magic bullet. The best evidence the investigators found indicates that healthy living is a person's best defense against dementia. That means eat right, exercise, treat health problems such as high blood pressure, and remain socially active. Of those interventions we were able to find that were tested, the few that showed potential for benefit or even hinting at benefit are really very similar to the kinds of public health messages we put out there in general about healthy aging, the lead researcher added. The researchers conducted four side-by-side evidence reviews to test different categories of proposed therapies and treatments for Alzheimer's. There is some moderate evidence that cognitive engagement brings some benefits, but those benefits are local. If we train on memory, our memory might improve. If we train on processing, our processing speed might improve. But there isn't any good evidence to directly link that to changes in how many people develop dementia. It doesn't rule out any possible treatments for dementia it just notes that science hasn't proven that any of them work. Further, it's a good sign that some evidence indicates that lifestyle changes like exercise and a healthy diet can help with dementia. We can all be doing these now because they aren't things that are going to hurt us, and will generalize to our health. Researchers need to return to the basics and focus on figuring out why people develop Alzheimer's before they start testing cures. If nothing else, these studies should lead seniors to stop spending money on online brain training programs.

SOURCE: HealthDay News, December 2017

Return to top

 
 
 Gene Therapy !

                                                   Gene Therapy Approved for Rare Inherited Vision-Loss Disorders

Luxturna, a form of gene therapy, has been approved to treat a rare group of inherited vision disorders that can lead to blindness. The disorders are broadly grouped together and known as biallelic RPE65 mutation-associated retinal dystrophy. They affect a combined 1,000 to 2,000 people in the United States, the U.S. Food and Drug Administration said Tuesday in a news release. Luxturna (voretigene neparvovec-rzyl) delivers a working copy of an existing defective gene that produces a retinal enzyme needed for normal vision. Today's approval marks another first in the field of gene therapy, both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss, said by lead researcher. I believe gene therapy will become a mainstay for treating, and maybe curing, many of our most devastating and intractable illnesses. Luxturna should be given only to people who have treatment-capable retinal cells, the agency said. Treatment must be done separately on each eye, at least six days apart. The treatment was evaluated in clinical trials involving 41 people ranging in age from 4 to 44. The most common side effects included eye redness, cataracts, increased eye pressure and retinal tear. Luxturna is produced by Spark Therapeutics, based in Philadelphia.

SOURCE: HealthDay News, December 2017

Return to top

 
 
 New Caner Drug !

                                                 New Cancer Drug Shows Promise against Wide Range of Tumors

A new drug that targets a genetic flaw common to most cancer cells is showing potency against many tumor types. The preliminary trial of a drug called ulixertinib was conducted with 135 patients who had already failed treatments for one of a variety of advanced, solid tumors. Ulixertinib did seem to spur at least a partial response to the therapy or disease stabilization, regardless of cancer type. It was exciting to see responses in some patients, the lead researcher added. The results of this study can be built upon to develop better treatment regimens for these patients. One cancer specialist explained how ulixertinib works on the cellular level. It inhibits the MAPK/ERK pathway, which is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. When one of the proteins in the pathway is mutated, it can become stuck in the 'on' or 'off' position, which is a necessary step in the development of many cancers. Ulixertinib effectively inhibits this broken cellular pathway, and that inhibition can be therapeutically exploited in multiple different cancers such as melanoma, lung, colon, and low-grade ovarian cancer. Ulixertinib targets the final regulator in the MAPK/ERK pathway, it might avoid cancer cells typical resistance to drug treatment. A great number of cancers including melanoma and lung cancers have mutations in the MAPK/ERK pathway, and while current therapies target proteins in this cascade, many patients develop resistance to current drugs, the lead researcher explained. The common denominator in these failed therapies is that the cancer has found a way to activate ERK. Therefore, the development of ERK inhibitors is a crucial next step to target this aberrant pathway. When it came to side effects, ulixertinib appeared to have a tolerable profile, with most issues not particularly severe, the lead researchers said.

SOURCE: HealthDay News, December 2017

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product RacedotTM  
  Generic Name Racecadotril
  Strength 100 mg
  Dosage form Tablet
  Therapeutic Category Anti diarrheal
  Product Cholenak IV InfusionTM
Generic Name

NaCl+KCl+Na Acetate  

Strength 0.5%+0.1%+0.393%
Dosage form IV Infusion
Therapeutic Category Parenteral Nutrition
  Product FodexilTM
  Generic Name Cefadroxil 
  Strength 1000 mg
  Dosage form Tablet
  Therapeutic Category Cephalosporin

Return to top

 

Copyright 2017 SQUARE Pharmaceuticals Ltd. All rights reserved.